Simplifying CMC: The value of an integrated drug substance and drug product strategy
Bringing a new therapy from concept to clinic requires a CMC strategy that connects decisions across the development lifecycle. This Almac Voice explores the value of integrating drug substance and drug product development, bringing together expertise in process chemistry, analytical development, physical sciences, formulation, manufacturing and regulatory support. It highlights how greater scientific alignment can help identify risks earlier, simplify knowledge transfer and support more informed decisions as programmes progress from preclinical development through clinical supply and commercialisation.
Read the full Almac Voice to discover how an integrated drug substance and drug product strategy can help simplify CMC development and reduce risk.